SurgiSil: Lip implant case shows looks can be deceiving

In October 2021, the Federal Circuit issued a two-and-half page decision in In re: SurgiSil, 14 F.4th 1380 (2021). Despite clocking in at just over 600 words, this small decision could have wide-ranging repercussions in the design patent jurisprudence, in three potential ways.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Hikma triumphs at SCOTUS in landmark skinny-label ruling

4 June 2026 Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma.

Americas

Heated LNP litigation puts Moderna and Acuitas in the spotlight

3 June 2026 A district court has thrown out one challenge over the vaccine delivery technology, while a separate appeal could affect protections available to government contractors during national emergencies.

Americas

J&J unit's valuable heart pump saved by 'rare' patent defence

1 June 2026 A district jury has handed a J&J unit a clean sweep in its defence against a rival's heart pump patent claims, delivering a win under the seldom-invoked reverse doctrine of equivalents.

More features

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Heated LNP litigation puts Moderna and Acuitas in the spotlight

J&J unit's valuable heart pump saved by 'rare' patent defence

Federal Circuit tosses $59m trade secrets judgment against EOFlow

Neal Gerber Eisenberg expands in Chicago with new litigator

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

SurgiSil: Lip implant case shows looks can be deceiving

More on this story

Editor's picks

Editor's picks

More features